-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
DKN-01 is a humanized monoclonal antibody against the DKK1 protein.
DKK1 is a protein that regulates the Wnt signaling pathway and is highly expressed in a variety of tumors.
it can help maintain the immune-suppressing tumor microenvironment around the tumor.
previously, DKN-01 was used in conjunction with Keytruda in a clinical trial for patients with advanced gastric esophagus connectivity in DKK1.
DKK1 can promote tumor growth by maintaining the tumor microenvironment (Photo Source: Leap's official website) Under the terms of the agreement, Leap will receive a $3 million advance payment from Baiji Shenzhou, which will receive an exclusive license to develop and promote DKN-01 in Asia (except Japan), Australia and New Zealand.
Leap will be eligible for an additional payment if Baiji Shenzhou decides to exercise its option based on the results of a subsequent preliminary proof-of-concept trial.
, Leap is eligible for potential milestone payments of up to $132 million, as well as DKN-01's sales share in the license area.
will make a $5 million equity investment in Leap as part of a simultaneous $27 million equity investment.
during the selection period, Leap agreed to conduct research on a combination of PD-1 antibodies developed by DKN-01 and Baiji Shenzhou, which is composed of tislelizumab.
Leap plans to evaluate the efficacy of DKN-01 and theritu zuma supra-anti-combination therapy in about 40 patients with second-line DKK1 high-expression gastric esophagus-connected adenocarcinoma/gastric cancer.
, Leap plans to evaluate the efficacy of DKN-01 in combination with dilla-bead monotherapy and chemotherapy in about 20 patients with first-line gastric esophagus-connected adenocarcinoma/gastric cancer.
Leap expects to launch these clinical trials in the first half of 2020. "We are pleased to be able to explore the combination of anti-PD-1 antibody dillizumab and DKN-01, which has so far been active lying with immunomarker-defined gastric cancer patients and immunocheckpoint inhibitors," said Dr. Yu Yong, Chief Medical Officer of Immuno-Oncology at Baiji Shenzhou,
.
's partnership with Leap Therapeutics is yet another example of our commitment to developing innovative treatments to meet the unmet medical needs of Asia and around the world. "Cooperation on further development of DKN-01 has been our top strategic priority," said Dr. Christopher K. Mirabelli, President and CEO of leap Therapeutics,
.
Is the ideal partner for Leap Therapeutics, with extensive experience in oncology drug development in the Asia Pacific region, and their expertise and products will support our efforts to meet the medical needs of esophageal/gastric, gynaecological and other cancers that are far from met.
" References: Leap Therapeutics and BeiGene Exclusive Announce Option s and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing, Retrieved Jan 03, 2020, from
Leap Therapeutics and Baiji Shenzhou Announce Exclusive Options and Licensing Agreements for DKN-01, Retrieved Carmichael 03, 2020, from
.3.